Page 126 - 《中国药科大学学报》2026年第1期

120 学报 Journal of China Pharmaceutical University 2026, 57(1): 115 − 121 第 57 卷

moschus manihot in treating chronic kidney diseases: a multi- ol, 2019, 1165: 165-194.
centre, open-label and single-arm clinical trial[J]. Phy- [31] Wu M, Yang ZF, Zhang CY, et al. Inhibition of NLRP3 inflam-
tomedicine, 2022, 99: 154011. masome ameliorates podocyte damage by suppressing lipid ac-
[18] Zhang L, Wang XZ, Chang L, et al. Quercetin improves diabet- cumulation in diabetic nephropathy[J]. Metabolism, 2021, 118:
ic kidney disease by inhibiting ferroptosis and regulating the 154748.
Nrf2 in streptozotocin-induced diabetic rats[J]. Ren Fail, 2024, [32] Wu W, Hu W, Han WB, et al. Inhibition of Akt/mTOR/p70S6K
46(1): 2327495. signaling activity with Huangkui capsule alleviates the early
[19] Zhao L, Han SY, Chai CZ. Huangkui capsule alleviates doxoru- glomerular pathological changes in diabetic nephropathy[J].
bicin-induced proteinuria via protecting against podocyte dam- Front Pharmacol, 2018, 9: 443.
age and inhibiting JAK/STAT signaling[J]. J Ethnopharmacol, [33] Wu L, Li Q, Liu SM, et al. Protective effect of hyperoside
2023, 306: 116150. against renal ischemia-reperfusion injury via modulating mito-
[20] Zhou JB, Zhang S, Sun XY, et al. Hyperoside ameliorates dia- chondrial fission, oxidative stress, and apoptosis[J]. Free Radic
betic nephropathy induced by STZ via targeting the miR-499- Res, 2019, 53(7): 727-736.
5p/APC axis[J]. J Pharmacol Sci, 2021, 146(1): 10-20. [34] Tang LX, Li K, Zhang Y, et al. Quercetin liposomes ameliorate
[21] Zhang KJ, Li MM, Yin KW, et al. Hyperoside mediates protec- streptozotocin-induced diabetic nephropathy in diabetic rats[J].
tion from diabetes kidney disease by regulating ROS-ERK sig- Sci Rep, 2020, 10(1): 2440.
naling pathway and pyroptosis[J]. Phytother Res, 2023, 37(12): [35] Liu YQ, Li Y, Xu L, et al. Quercetin attenuates podocyte apop-
5871-5882. tosis of diabetic nephropathy through targeting EGFR
[22] Yang ZJ, Wang HR, Wang YI, et al. Myricetin attenuated dia- signaling[J]. Front Pharmacol, 2022, 12: 792777.
betes-associated kidney injuries and dysfunction via regulating [36] Hao HH, Shao ZM, Tang DQ, et al. Preventive effects of rutin
nuclear factor (erythroid derived 2)-like 2 and nuclear factor-κB on the development of experimental diabetic nephropathy in
signaling[J]. Front Pharmacol, 2019, 10: 647. rats[J]. Life Sci, 2012, 91(19/20): 959-967.
[23] Wu CH, Tang HT, Cui X, et al. A single-cell profile reveals the [37] Djudjaj S, Boor P. Cellular and molecular mechanisms of kid-
transcriptional regulation responded for Abelmoschus manihot ney fibrosis[J]. Mol Aspects Med, 2019, 65: 16-36.
(L.) treatment in diabetic kidney disease[J]. Phytomedicine, [38] Li W, He WM, Xia P, et al. Total extracts of Abelmoschus
2024, 130: 155642. manihot L. attenuates adriamycin-induced renal tubule injury
[24] Tu Y, Sun W, Wan YG, et al. Huangkui capsule, an extract via suppression of ROS-ERK1/2-mediated NLRP3 inflamma-
from Abelmoschus manihot (L. ) medic, ameliorates adri- some activation[J]. Front Pharmacol, 2019, 10: 567.
amycin-induced renal inflammation and glomerular injury via [39] Zhu Z, Luan GX, Peng SQ, et al. Huangkui capsule attenuates
inhibiting p38MAPK signaling pathway activity in rats[J]. J diabetic kidney disease through the induction of mitophagy me-
Ethnopharmacol, 2013, 147(2): 311-320. diated by STING1/PINK1 signaling in tubular cells[J]. Phy-
[25] Lalitha N, Sadashivaiah B, Ramaprasad TR, et al. Anti-hyper- tomedicine, 2023, 119: 154975.
glycemic activity of myricetin, through inhibition of DPP-4 and [40] Mao ZM, Shen SM, Wan YG, et al. Huangkui capsule attenu-
enhanced GLP-1 levels, is attenuated by co-ingestion with ates renal fibrosis in diabetic nephropathy rats through regulat-
lectin-rich protein[J]. PLoS One, 2020, 15(4): e0231543. ing oxidative stress and p38MAPK/Akt pathways, compared to
[26] Yan L, Vaghari-Tabari M, Malakoti F, et al. Quercetin: an ef- α-lipoic acid[J]. J Ethnopharmacol, 2015, 173: 256-265.
fective polyphenol in alleviating diabetes and diabetic complica- [41] Gu LY, Yun-Sun, Tang HT, et al. Huangkui capsule in combi-
tions[J]. Crit Rev Food Sci Nutr, 2023, 63(28): 9163-9186. nation with metformin ameliorates diabetic nephropathy via the
[27] Li ZY, Liao WZ, Yin XX, et al. Hyperoside attenuates Cd-in- Klotho/TGF-β1/p38MAPK signaling pathway[J]. J Ethnophar-
duced kidney injury via inhibiting NLRP3 inflammasome acti- macol, 2021, 281: 113548.
vation and ROS/MAPK/NF-κB signaling pathway in vivo and in [42] Xu WL, Zhou PP, Yu X, et al. Myricetin induces M2
vitro[J]. Food Chem Toxicol, 2023, 172: 113601. macrophage polarization to alleviate renal tubulointerstitial fi-
[28] Wang B, Liu D, Zhu QH, et al. Rutin ameliorates kidney inter- brosis in diabetic nephropathy via PI3K/Akt pathway[J]. World
stitial fibrosis in rats with obstructive nephropathy[J]. Int Im- J Diabetes, 2024, 15(1): 105-125.
munopharmacol, 2016, 35: 77-84. [43] Yuan NN, Diao JX, Dong JM, et al. Targeting ROCK1 in dia-
[29] Khajevand-Khazaei MR, Mohseni-Moghaddam P, Hosseini M, betic kidney disease: Unraveling mesangial fibrosis mecha-
et al. Rutin, a quercetin glycoside, alleviates acute endotoxemic nisms and introducing myricetin as a novel antagonist[J].
kidney injury in C57BL/6 mice via suppression of inflamma- Biomed Pharmacother, 2024, 171: 116208.
tion and up-regulation of antioxidants and SIRT1[J]. Eur J [44] Dong RX, Zhang X, Liu YD, et al. Rutin alleviates EndMT by
Pharmacol, 2018, 833: 307-313. restoring autophagy through inhibiting HDAC1 via
[30] Zhao JH. Mesangial cells and renal fibrosis[J]. Adv Exp Med Bi- PI3K/AKT/mTOR pathway in diabetic kidney disease[J]. Phy-